Tgf Beta Pathway Activation Is A Predictor Of Progression Free And Overall Survival In Advanced High-Grade Serous Ovarian Cancer According To The Surgical Aggressiveness And Rate Of Cytoreduction Of Different Oncologic Centers

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER(2019)

引用 0|浏览0
暂无评分
摘要
Introduction/Background The activation of TGFβ pathway in advanced stage high-grade serous ovarian cancer (HGSOC) has been found to be related to short progression free survival (PFS) and overall survival (OS). miRNA181a-5p was found to be a proxy of TGFβ activation. This prognostic role has been identified only in cohorts with low surgical complexity, we evaluated 2 cohorts with different surgical approaches. Methodology Series of HGSEOC from two centers (European Institute of Oncology, Milan, Cohort1; San Gerardo Hospital, Monza, Cohort2) were analyzed for clinical features and miRNA quantification to test their prognostic value using a Cox-proportional hazard regression model. Results 118 and 84 patients were included, respectively. Cohort1 versus Cohort2 was composed of similar FIGO stages, higher upper abdominal disease spread (UAD) (P An optimized threshold of miR181a-5p expression to segregate patients according to their prognosis was identified (miR-low and miR-high): for Cohort1 no threshold was reached; for Cohort2 a threshold segregated PFS of 20.9 v. 9.6 months (P:0.0008) and OS of 60.3 v. 23.3 months (P:0.0008), respectively. In multivariate analysis, no significance was observed for miR-high in Cohort1. For Cohort2, miR-high was related to worse PFS (P:0.0002), and OS (P:0.007). Conclusion miR181a-5p was observed as a prognostic biomarker in HGSEOC in Cohort2, -less aggressive surgery-, instead no prognostic role was observed in Cohort 1 -aggressive surgery-. This question-generating analysis suggests that TGFβ activation, a proxy of tumor aggressiveness, might be withdrawn by an aggressive surgical approach. A prospective validation of miR181 role is needed, the translational ancillary study of the TRUST trial (NCT # 02828618) may answer this question. Disclosure Nothing to disclose.
更多
查看译文
关键词
serous ovarian cancer,pathway activation,high-grade
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要